eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression
Open Access
- 3 November 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0360244
Abstract
Background: The COVID-19 pandemic highlighted the critical unmet need for novel targets, biomarkers, and effective pharmacotherapies to reduce the severity/mortality of COVID pneumonia and progression to acute respiratory distress syndrome (ARDS). Extracellular NAMPT (eNAMPT) is a druggable DAMP and TLR4 ligand centrally involved in ARDS pathobiology. We explored the utility of plasma eNAMPT measurements as a potential COVID-19 biomarker linked to ARDS progression and disease severity and investigated the potential cellular source for eNAMPT release/secretion in COVID-19 subjects. Methods: A plasma biomarker panel of inflammatory cytokines (IL-1β, IL-6, IL-8, IL-1RA, TNF-α), DAMPs (eNAMPT, MIF) and vascular proteins (ANG-2, PSGL-1) were evaluated in three distinct COVID-19-positive cohorts (Miami, Arizona, Tampa) (n = 277) and healthy control subjects (n = 214). Single-cell RNA sequencing (scRNA-seq) publicly available on peripheral blood mononuclear cells (PBMCs) in a subset of Tampa COVID-19 survivors (n = 18) and an autopsied COVID lung tissue database was separately analyzed for biomarker gene expression. Results: Plasma biomarkers, including eNAMPT were significantly elevated in COVID-19 subjects compared to healthy controls (p < 0.0001), with IL-1RA, IL-6 and eNAMPT exhibiting the strongest diagnostic performance. Biomarker levels (all except IL-8, MIF) were higher in COVID-19 ARDS cases vs COVID-19 pneumonia (n = 154, AUC 0.71–0.79, p < 0.05) and were significantly elevated in COVID non-survivors (IL-6, IL-1RA, TNF-α, eNAMPT, ANG-2, PSGL-1) compared to survivors (p < 0.05). NAMPT gene expression was significantly upregulated in COVID-19 PBMCs compared with healthy controls, most evident within the CD14 + monocyte cluster. Relative to lung tissue from non-COVID-19 infected, NAMPT gene expression was increased in specific COVID-19 lung cell populations, including neutrophils, CD16 + monocytes, conventional dendritic cells (cDCs), fibroblasts, endothelium, and alveolar macrophages. Conclusion: Our study corroborated the utility of this biomarker panel for diagnostic and severity assessment in COVID-19- associated ARDS and as a strategy for subject stratification in therapeutic trials of eNAMPT-neutralizing therapies. We further identified NAMPT expression in immune effector cells that correlates with COVID-19 severity and lethality. Together, these findings suggest NAMPT plays a key role in sustaining inflammatory activation and impairing lung regeneration in fatal COVID-19.Keywords
Funding Information
- Division of Intramural Research (PO1HL126609)
- Division of Intramural Research (R44HL145930)
- Division of Intramural Research (RO1HL141387)
This publication has 26 references indexed in Scilit:
- The Ang2:Tie2 Axis Regulates Pulmonary Vascular Endothelial Cell Injury and Activation Responsible for the Development of Idiopathic Pneumonia Syndrome Following Allogeneic Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2026
- Predictive modeling of ARDS mortality integrating biomarker/cytokine, clinical and metabolomic dataTranslational Research, 2025
- Impact of P-selectin–PSGL-1 Axis on Platelet-Endothelium-Leukocyte Interactions in Fatal COVID-19Laboratory Investigation, 2023
- The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19Inflammation Research, 2022
- Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralizationTranslational Research, 2022
- SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosisCell, 2021
- Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injuryTranslational Research, 2021
- COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targetsNature, 2021
- Interleukin‐6 in Covid‐19: A systematic review and meta‐analysisReviews in Medical Virology, 2020
- Nuclear factor k B: a pivotal role in the systemic inflammatory response syndrome and new target for therapyIntensive Care Medicine, 1998